Iontophoresis for Treatment of Peyronie’s Disease

Riedl, Claus R.; Plas, Eugen; Engelhardt, Paul F.; Daha, Kurosch; Pflüger, Heinz

doi:10.1016/s0022-5347(05)67981-5

Cited by 78 publications

(42 citation statements)

References 34 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…48 Two nonrandomized trials examined the efficacy of topically applied verapamil with enhanced penetration using iontophoresis. In the first study by Reidl et al, 49 100 men received a combination of verapamil, dexamethasone, and lidocaine delivered with an energy of 2 milliamperes (mA) weekly from 3 to 53 weeks. A total of 96% of patients noted a reduction in pain, 53% a reduction in plaque size, and subjective improvement of curvature was reported in 37% with 16% of patients noting complete or greater than 301 of improvement.…”

Section: External Energy Therapymentioning

confidence: 99%

Review of current nonsurgical management of Peyronie's disease

Levine

2003

Int J Impot Res

View full text Add to dashboard Cite

The current nonsurgical treatment options for men with Peyronie's disease is reviewed. The treatments currently employed and published in the English literature are discussed. A wide variety of nonsurgical treatment options are available to the practicing physician, including oral and topical medications, intralesional injection therapy, as well as employing external energy sources to drive medicine into the tunica albuginea by iontophoresis or direct stimulation of plaque change by shock wave therapy. Nonsurgical treatment of Peyronie's disease clearly has a place in the armamentarium of the practicing urologist. Oral therapy appears to have little therapeutic benefit. Injection and topical approaches deserve further attention. Yet, no single treatment stands out as the most effective remedy for all men with Peyronie's disease. Further controlled, large-scale studies are necessary to establish the benefits of these nonsurgical approaches. In the meantime, combination therapy appears to make sense in the nonsurgical treatment of men with Peyronie's disease.

show abstract

Section: External Energy Therapymentioning

confidence: 99%

Review of current nonsurgical management of Peyronie's disease

Levine

2003

Int J Impot Res

View full text Add to dashboard Cite

show abstract

“…Riedl et al 121 used the self adhesive iontophoretic patch in the treatment of PD and reported that iontophoresis of dexamethasone, lidocaine and verapamil is effective for peyronie's disease and especially beneficial for painful lesions of less than 12 months in duration and for deviations less than 60 degrees. In their opinion, this procedure should be regarded as first line noninvasive therapy for PD 121 .…”

Section: Peyronie's Disease Treatmentmentioning

confidence: 99%

“…In their opinion, this procedure should be regarded as first line noninvasive therapy for PD 121 . Thus, iontophoresis presents a potential area of development for drug delivery in patients with PD and other penile disorders.…”

Section: Peyronie's Disease Treatmentmentioning

confidence: 99%

Advances in iontophoresis for drug delivery

Dehghan¹,

Mouzam²

2010

Int J Health Res

View full text Add to dashboard Cite

an online international journal allowing free unlimited access to abstract and full-text of published articles. The journal is devoted to the promotion of health sciences and related disciplines (including medicine, pharmacy, nursing, biotechnology, cell and molecular biology, and related engineering fields). It seeks particularly (but not exclusively) to encourage multidisciplinary research and collaboration among scientists, the industry and the healthcare professionals. It will also provide an international forum for the communication and evaluation of data, methods and findings in health sciences and related disciplines. The journal welcomes original research papers, reviews and case reports on current topics of special interest and relevance. All manuscripts will be subject to rapid peer review. Those of high quality (not previously published and not under consideration for publication) will be published without delay. The maximum length of manuscripts should normally be 10,000 words (20 single-spaced typewritten pages) for review, 6,000 words for research articles, 3,000 for technical notes, case reports, commentaries and short communications. Submission of Manuscript:The International Journal of Health Research uses a journal management software to allow authors track the changes to their submission. All manuscripts must be in MS Word and in English and should be submitted online at http://www.ijhr.org. Authors who do not want to submit online or cannot submit online should send their manuscript by e-mail attachment (in single file) to the editorial office below. Submission of a manuscript is an indication that the content has not been published or under consideration for publication elsewhere. Authors may submit the names of expert reviewers or those they do not want to review their papers. Enquiries

show abstract

“…In 1995 Montorsi et al [41] reported the use of iontophoresis carrying dexametasone and verapamil in PD treatment, with satisfactory results. A relatively recent study [42] exposed 100 men to iontopheresis carrying dexamethasone, lidocaine, and verapamil. In this study 96% of the men reported less pain, 37% described a subjective improvement in curvature, and 53% experienced a reduction in plaque size; 15% of the patients had recurrence of their disease after 5.5 months.…”

Section: Topical Treatmentmentioning

confidence: 99%

Peyronie’s Disease: Lights and Shadows

et al. 2007

View full text Add to dashboard Cite

Peyronie’s disease (PD) is characterized by the onset of fibrous plaque inside the tunica albuginea of the penile corpora cavernosa that can cause pain and bending during the erection, making intercourse difficult or impossible. Evidence of the literature supports the autoimmune etiology of PD and suggests genetic and familiar conditions, penile traumatisms, and a history of genital tract diseases as risk factors, but no definitive conclusions arise about the pathogenesis of the disease. Few randomized trials demonstrated that medical therapies, such as vitamin E, colchicine, potassium aminobenzoate, tamoxifen, and injection therapy with verapamil, can stabilize the acute phase of the disease. Extracorporeal shock wave therapy and iontophoresis cannot be considered first-line or gold standard therapies. Satisfactory results have been published with the Nesbit operation in large series with low-stage disease, whereas plication procedures have shown significant relapse rates. A high incidence of long-term penile retractions has been reported in high-stage disease treated with plaque incision and simple graft insertion. Malleable, soft, or inflatable prostheses combined with graft implantation have given the best results in terms of penile straightening and lengthening and patient satisfaction. In conclusion, the etiopathogenesis of PD is not yet clearly understood, no medical therapy is fully effective, and surgery remains the gold standard in patients with severe deformity and/or erectile dysfunction.

show abstract

Iontophoresis for Treatment of Peyronie’s Disease

Abstract: Iontophoresis of dexamethasone, lidocaine and verapamil may be regarded as first line nonsurgical treatment for Peyronie's disease.

Cited by 78 publications

References 34 publications

Review of current nonsurgical management of Peyronie's disease

Review of current nonsurgical management of Peyronie's disease

Advances in iontophoresis for drug delivery

Peyronie’s Disease: Lights and Shadows

Contact Info

Product

Resources

About